{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:15:30Z","timestamp":1790612130618,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:00:00Z","timestamp":1585958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:00:00Z","timestamp":1585958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"publisher","award":["2018YFC1311900"],"award-info":[{"award-number":["2018YFC1311900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010903","name":"Key Programme","doi-asserted-by":"publisher","award":["91859203"],"award-info":[{"award-number":["91859203"]}],"id":[{"id":"10.13039\/501100010903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010905","name":"Major Research Plan","doi-asserted-by":"publisher","award":["81871890"],"award-info":[{"award-number":["81871890"]}],"id":[{"id":"10.13039\/501100010905","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Program from the Department of Science and Technology, Sichuan Province","award":["2017SZ0052"],"award-info":[{"award-number":["2017SZ0052"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s10637-020-00932-3","type":"journal-article","created":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T12:04:07Z","timestamp":1586001847000},"page":"1627-1632","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Dasatinib-induced chylothorax: report of a case and review of the literature"],"prefix":"10.1007","volume":"38","author":[{"given":"Bojiang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuohong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,4]]},"reference":[{"key":"932_CR1","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.3389\/fimmu.2018.03133","volume":"9","author":"K Guo","year":"2018","unstructured":"Guo K, Bu X, Yang C, Cao X, Bian H, Zhu Q et al (2018) Treatment effects of the second-generation tyrosine kinase inhibitor Dasatinib on autoimmune arthritis. Front Immunol 9:3133","journal-title":"Front Immunol"},{"issue":"7","key":"932_CR2","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","volume":"129","author":"D Rea","year":"2017","unstructured":"Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, Gardembas M, Coiteux V, Guillerm G, Legros L, Etienne G, Pignon JM, Villemagne B, Escoffre-Barbe M, Ianotto JC, Charbonnier A, Johnson-Ansah H, Noel MP, Rousselot P, Mahon FX, France Intergroupe des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques (2017) Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 129(7):846\u2013854","journal-title":"Blood."},{"issue":"3","key":"932_CR3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Kantarjian H (2018) Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol 93(3):442\u2013459","journal-title":"Am J Hematol"},{"issue":"2","key":"932_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cncr.24734","volume":"116","author":"K Porkka","year":"2010","unstructured":"Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE (2010) Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 116(2):377\u2013386","journal-title":"Cancer."},{"issue":"1","key":"932_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3324\/haematol.2018.188987","volume":"104","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE (2019) Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica. 104(1):93\u2013101","journal-title":"Haematologica."},{"issue":"1","key":"932_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40265-016-0677-x","volume":"77","author":"GM Keating","year":"2017","unstructured":"Keating GM (2017) Dasatinib: a review in chronic myeloid Leukaemia and Ph+ acute lymphoblastic Leukaemia. Drugs. 77(1):85\u201396","journal-title":"Drugs."},{"issue":"6","key":"932_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40272-018-0319-8","volume":"20","author":"EH McCafferty","year":"2018","unstructured":"McCafferty EH, Dhillon S, Deeks ED (2018) Dasatinib: a review in pediatric chronic myeloid leukemia. Paediatr Drugs 20(6):593\u2013600","journal-title":"Paediatr Drugs"},{"key":"932_CR8","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.3389\/fimmu.2018.03152","volume":"9","author":"MC Chang","year":"2018","unstructured":"Chang MC, Cheng HI, Hsu K, Hsu YN, Kao CW, Chang YF et al (2018) NKG2A Down-regulation by Dasatinib enhances natural killer cytotoxicity and accelerates effective treatment responses in patients with chronic myeloid leukemia. Front Immunol 9:3152","journal-title":"Front Immunol"},{"issue":"1","key":"932_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1182\/blood-2016-08-734947","volume":"129","author":"S Nishiwaki","year":"2017","unstructured":"Nishiwaki S, Maeda M, Yamada M, Okuno S, Harada Y, Suzuki K et al (2017) Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients. Blood. 129(1):126\u2013128","journal-title":"Blood."},{"issue":"3","key":"932_CR10","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.25342","volume":"94","author":"J Cortes","year":"2019","unstructured":"Cortes J, Rea D, Lipton JH (2019) Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol 94(3):346\u2013357","journal-title":"Am J Hematol"},{"issue":"3","key":"932_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3324\/haematol.2012.064337","volume":"98","author":"A Russo Rossi","year":"2013","unstructured":"Russo Rossi A, Breccia M, Abruzzese E, Castagnetti F, Luciano L, Gozzini A, Annunziata M, Martino B, Stagno F, Cavazzini F, Tiribelli M, Visani G, Pregno P, Musto P, Fava C, Sgherza N, Albano F, Rosti G, Alimena G, Specchia G (2013) Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. Haematologica. 98(3):399\u2013403","journal-title":"Haematologica."},{"issue":"20","key":"932_CR12","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A (2016) Final 5-year study results of DASISION: the Dasatinib versus Imatinib study in treatment-Na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol 34(20):2333\u20132340","journal-title":"J Clin Oncol"},{"issue":"2","key":"932_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/hon.2020","volume":"31","author":"R Latagliata","year":"2013","unstructured":"Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G (2013) Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol 31(2):103\u2013109","journal-title":"Hematol Oncol"},{"issue":"5","key":"932_CR14","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/bjh.15702","volume":"184","author":"JM Umakanthan","year":"2019","unstructured":"Umakanthan JM, Iqbal J, Batlevi CL, Bouska A, Smith LM, Shostrom V, Nutsch H, William BM, Gregory Bociek R, Lunning M, Bierman P, Younes A, Armitage JO, Vose JM (2019) Phase I\/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma. Br J Haematol 184(5):744\u2013752","journal-title":"Br J Haematol"},{"issue":"3","key":"932_CR15","doi-asserted-by":"publisher","first-page":"7474","DOI":"10.4081\/hr.2018.7474","volume":"10","author":"A Nakaya","year":"2018","unstructured":"Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, Hotta M, Yoshimura H, Ishii K, Ito T, Nomura S (2018) Clinical significance of dasatinib-induced pleural effusion in patients with de novo chronic myeloid leukemia. Hematol Rep 10(3):7474","journal-title":"Hematol Rep"},{"issue":"2","key":"932_CR16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.critrevonc.2013.10.005","volume":"89","author":"S Paydas","year":"2014","unstructured":"Paydas S (2014) Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect? Crit Rev Oncol Hematol 89(2):242\u2013247","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"932_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/jcpt.12107","volume":"39","author":"G Kaiafa","year":"2014","unstructured":"Kaiafa G, Kakaletsis N, Savopoulos C, Perifanis V, Giannouli A, Papadopoulos N, Zisekas S, Hatzitolios AI (2014) Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report. J Clin Pharm Ther 39(1):102\u2013105","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"932_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4274\/tjh.2012.0196","volume":"32","author":"YM Huang","year":"2015","unstructured":"Huang YM, Wang CH, Huang JS, Yeh KY, Lai CH, Wu TH, Chang PH, Chang PH, Chang YS, Lan YJ (2015) Dasatinib-related chylothorax. Turk J Haematol 32(1):68\u201372","journal-title":"Turk J Haematol"},{"issue":"1","key":"932_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/08998280.2017.11929535","volume":"30","author":"ZQ Baloch","year":"2017","unstructured":"Baloch ZQ, Abbas SA, Bhatti H, Braver Y, Ali SK (2017) Dasatinib-induced chylothorax in chronic myeloid leukemia. Proc (Bayl Univ Med Cent) 30(1):71\u201373","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"4","key":"932_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.4103\/1817-1737.191871","volume":"11","author":"L Ferreiro","year":"2016","unstructured":"Ferreiro L, San-Jos\u00e9 E, Su\u00e1rez-Antelo J, Vald\u00e9s L (2016) Dasatinib-induced pleural effusion: Chylothorax, an option to consider. Ann Thorac Med 11(4):289\u2013293","journal-title":"Ann Thorac Med"},{"issue":"5","key":"932_CR21","first-page":"1348","volume":"24","author":"L Yang","year":"2016","unstructured":"Yang L, Lu N, Jing Y, Yu L (2016) Chylothorax related with Dasatinib in the treatment of chronic myeloid leukemia: report of 3 cases. Zhongguo Shi Yan Xue Ye Xue Za Zhi 24(5):1348\u20131353","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"7","key":"932_CR22","doi-asserted-by":"publisher","first-page":"867","DOI":"10.4065\/80.7.867","volume":"80","author":"CH Doerr","year":"2005","unstructured":"Doerr CH, Allen MS, Nichols FC 3rd, Ryu JH (2005) Etiology of chylothorax in 203 patients. Mayo Clin Proc 80(7):867\u2013870","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"932_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40463-016-0166-y","volume":"45","author":"V Merki","year":"2016","unstructured":"Merki V, Pichler J, Giger R, Mantokoudis G (2016) Chylothorax in thyroid surgery: a very rare case and systematic review of the literature. J Otolaryngol Head Neck Surg 45(1):52","journal-title":"J Otolaryngol Head Neck Surg"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00932-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-00932-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00932-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T14:23:24Z","timestamp":1695997404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-00932-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,4]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["932"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-00932-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,4]]},"assertion":[{"value":"2 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study conformed to the Declaration of Helsinki and was approved by the Ethics Committee of West China Hospital, Sichuan University, China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}